Indegene Limited Reappoints Neeraj Bharadwaj as Independent Director for 5 Years

Indegene Limited , a prominent player in the Indian healthcare technology sector, has announced a significant board development. The company's Board of Directors approved the reappointment of Mr. Neeraj Bharadwaj as Non-Executive Independent Director for a five-year term on December 19, 2025, marking his return to the board in a new capacity.

Board Appointment Details

The board approval came based on the recommendation of the Nomination and Remuneration Committee. The appointment details are outlined below:

Parameter:	Details
Director Name:	Mr. Neeraj Bharadwaj
DIN:	01314963
Position:	Non-Executive Independent Director
Term Duration:	5 years
Effective Period:	January 25, 2026 to January 24, 2031
Approval Required:	Shareholder approval through Postal Ballot

Director Profile and Qualifications

Mr. Bharadwaj brings substantial academic credentials and professional experience to the board. He holds a Bachelor of Science in Economics with a specialization in Finance from the University of Pennsylvania, Philadelphia, and an MBA in Management from Harvard University, Cambridge, Massachusetts.

His professional expertise spans multiple areas:

Expertise Area:	Details
Core Competencies:	Private equity, investment management, strategic leadership
Investment Experience:	Led and managed large-scale investments across diverse sectors
Specialized Knowledge:	Finance, business strategy, corporate governance
Leadership Roles:	Prominent positions in global and national organizations

Regulatory Compliance and Governance

Indegene Limited has ensured full compliance with regulatory requirements for this appointment. The company confirmed that Mr. Bharadwaj is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority, as required under NSE and BSE circulars.

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also confirmed that Mr. Bharadwaj is not related to any existing Director of the company.

Additional Board Matters

During the same board meeting, the directors also approved allotments under the company's ESOP Plan 2020 and RSU Plan 2020, demonstrating continued focus on employee incentive programs.

Srishti Ramesh Kaushik, Company Secretary and Compliance Officer of Indegene Limited, confirmed that all relevant information has been made available on the company's official website at https://www.indegene.com/ .

This reappointment reflects the company's confidence in Mr. Bharadwaj's expertise and his potential contribution to Indegene's strategic direction in the evolving healthcare technology sector.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.18%	-5.89%	-9.56%	-16.44%	-28.64%	-15.78%

Indegene , a digital-first life sciences commercialization company, has announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) technology. This innovative tool aims to streamline complex medical writing workflows across clinical development, regulatory submissions, and beyond.

Revolutionizing Medical Writing

NEXT Medical Writing Automation is designed to address the challenges faced by medical writing teams, who are often under pressure to deliver precise, regulatory-ready documents within tight deadlines. The platform operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows.

Key Features and Benefits

Integration with Existing Systems: NEXT seamlessly integrates with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents.
Efficiency Boost: The platform offers automated scheduling, intelligent task assignments, and robust data flow integration, helping life sciences organizations scale operations efficiently.
Compliance Focus: While enhancing efficiency, NEXT maintains a strong compliance backbone, crucial in an environment of growing document requirements and increased scrutiny.

Leveraging Cortex AI Engine

At the heart of NEXT is Indegene's Cortex AI engine, a life sciences-specialist knowledge engineering and multi-agent orchestration platform. Cortex enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance.

Industry Impact

Sameer Lal, SVP, Enterprise Medical Solutions at Indegene, commented on the launch: "We see this platform as more than automation—it's about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting."

About Indegene

Indegene Limited is a digital-first, life sciences commercialization company. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get them to market, and grow their impact through the life cycle in a more effective, efficient, and modern way.

The launch of NEXT Medical Writing Automation reinforces Indegene's commitment to building AI-driven, domain-first solutions that help life sciences organizations modernize critical processes and meet business objectives with confidence.

For more information about Indegene and its services, visit www.indegene.com .